Literature DB >> 11709515

Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue.

S Daum1, D Weiss, M Hummel, R Ullrich, W Heise, H Stein, E O Riecken, H D Foss.   

Abstract

BACKGROUND: Clonal T cell receptor (TCR) gene rearrangements and loss of T cell antigens such as CD8 and TCR-beta in intraepithelial lymphocytes (IELs) may indicate the development of an enteropathy-type intestinal T cell lymphoma (EITCL) in patients with refractory sprue. AIMS: To define the diagnostic value of these markers in duodenal biopsies from patients with villous atrophy as a result of various underlying disorders. PATIENTS AND METHODS: Duodenal biopsies from eight patients with coeliac disease and five patients with villous atrophy caused by defined disorders were compared with three patients with refractory sprue evolving into overt EITCL, two patients with ulcerative jejunitis, and with eight patients with overt EITCL, for expression of CD3, CD4, CD8, and TCR-beta in IELs using immunohistochemistry and for clonal TCR-gamma gene rearrangements using polymerase chain reaction. In addition, biopsies from six consecutive patients with refractory sprue of uncertain cause were examined.
RESULTS: Clonal TCR-gamma gene rearrangements were found in all resected tumours of patients with EITCL, in 3/8 duodenal biopsies of patients with EITCL, in 2/2 patients with ulcerative jejunitis, in 2/3 patients with refractory sprue evolving into overt EITCL, and in 1/6 patients with refractory sprue. No rearrangements were found in biopsies from patients with refractory sprue caused by defined disorders or those with coeliac disease. Clonality in duodenal biopsies was associated with an abnormal phenotype of IELs in all cases and in all but one case in patients with evidence of underlying coeliac disease. Specificity for detection of an EITCL using immunohistology was 77% for CD8 and for TCR-beta staining, and 100% for detection of a clonal TCR-gamma gene rearrangement. Sensitivity was 62% for staining with CD8 and clonality investigation, while sensitivity reached 100% for TCR-beta staining in all investigated patients with EITCL.
CONCLUSIONS: Clonal proliferations of phenotypically abnormal IELs in refractory sprue represent an early manifestation of EITCL, for which the term "sprue-like intestinal T cell lymphoma" is proposed. This constellation is also found in duodenal biopsies from patients with an overt EITCL and is not related to other sprue syndromes, resulting in a high specificity for detection of an EITCL or refractory sprue evolving into EITCL. Overt EITCL may develop directly from coeliac disease without a precursor lesion (refractory sprue with clonal IELs) being demonstrable in duodenal biopsies or via a "sprue-like intestinal T cell lymphoma". This latter entity is a complication of coeliac disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709515      PMCID: PMC1728529          DOI: 10.1136/gut.49.6.804

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  Simultaneous occurrence of autoimmune enteropathy and recurrent deep venous thrombosis.

Authors:  N C Pirisi-Hauck; H D Foss; J Baier; S Kurunczi
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-03       Impact factor: 2.839

2.  Identification of a T cell lymphoma category derived from intestinal-mucosa-associated T cells.

Authors:  H Stein; D Dienemann; M Sperling; M Zeitz; E O Riecken
Journal:  Lancet       Date:  1988-11-05       Impact factor: 79.321

3.  Intraepithelial T cells of the TcR gamma/delta+ CD8- and V delta 1/J delta 1+ phenotypes are increased in coeliac disease.

Authors:  T S Halstensen; H Scott; P Brandtzaeg
Journal:  Scand J Immunol       Date:  1989-12       Impact factor: 3.487

4.  Changes in intraepithelial lymphocyte subpopulations in coeliac disease and enteropathy associated T cell lymphoma (malignant histiocytosis of the intestine).

Authors:  J Spencer; T T MacDonald; T C Diss; J A Walker-Smith; P J Ciclitira; P G Isaacson
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

5.  Clonal T-cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: a critical evaluation.

Authors:  E Dippel; C Assaf; M Hummel; H J Schrag; H Stein; S Goerdt; C E Orfanos
Journal:  J Pathol       Date:  1999-06       Impact factor: 7.996

6.  Collagenous sprue--an unrecognized type of malabsorption.

Authors:  W M Weinstein; D R Saunders; G N Tytgat; C E Rubin
Journal:  N Engl J Med       Date:  1970-12-10       Impact factor: 91.245

7.  Celiac sprue and refractory sprue.

Authors:  J S Trier; Z M Falchuk; M C Carey; D S Schreiber
Journal:  Gastroenterology       Date:  1978-08       Impact factor: 22.682

8.  Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes.

Authors:  J Spencer; N Cerf-Bensussan; A Jarry; N Brousse; D Guy-Grand; A S Krajewski; P G Isaacson
Journal:  Am J Pathol       Date:  1988-07       Impact factor: 4.307

9.  Malignancy in coeliac disease--effect of a gluten free diet.

Authors:  G K Holmes; P Prior; M R Lane; D Pope; R N Allan
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

10.  Coeliac disease, gluten-free diet, and malignancy.

Authors:  G K Holmes; P L Stokes; T M Sorahan; P Prior; J A Waterhouse; W T Cooke
Journal:  Gut       Date:  1976-08       Impact factor: 23.059

View more
  25 in total

1.  Gastrointestinal intraepithelial lymphocytes and T cell lymphomas.

Authors:  I N Farstad; K E A Lundin
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

Review 2.  Refractory sprue.

Authors:  Andrea N Culliford; Peter H R Green
Journal:  Curr Gastroenterol Rep       Date:  2003-10

3.  From hyperplasia to T cell lymphoma.

Authors:  N Cerf-Bensussan; N Brousse; C Cellier
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 4.  CD4+ T-cell lymphoproliferative disorder of the gut clinically mimicking celiac sprue.

Authors:  Jaroslav Zivny; Barbara F Banner; Sanjay Agrawal; German Pihan; Graham F Barnard
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

Review 5.  Hematologic manifestations of celiac disease.

Authors:  Thorvardur R Halfdanarson; Mark R Litzow; Joseph A Murray
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

Review 6.  An approach to duodenal biopsies.

Authors:  S Serra; P A Jani
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

7.  Successful treatment of enteropathy-associated T cell lymphoma with autologous stem cell transplant.

Authors:  Catherine Rongey; Ivana Micallef; Thomas Smyrk; Joseph Murray
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

8.  CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review.

Authors:  Sheetal M Kircher; Sandeep Gurbuxani; Sonali M Smith
Journal:  J Gastrointest Cancer       Date:  2007

9.  CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review.

Authors:  Sheetal M Kircher; Sandeep Gurbuxani; Sonali M Smith
Journal:  J Gastrointest Cancer       Date:  2007

10.  Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience.

Authors:  A Al-Toma; W H M Verbeek; M Hadithi; B M E von Blomberg; C J J Mulder
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.